{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:39:25Z","timestamp":1747172365774,"version":"3.40.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.wneu.2024.04.066","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T16:01:58Z","timestamp":1713369718000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review"],"prefix":"10.1016","volume":"188","author":[{"given":"Huai-peng","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-liang","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-0717","authenticated-orcid":false,"given":"Xiao-wu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2024.04.066_bib1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.wneu.2024.04.066_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A\u00a0uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Bro\u00ebt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2024.04.066_bib4","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5045\/br.2020.S010","article-title":"Recent advances in the management of primary central nervous system lymphoma","volume":"55","author":"Choi","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.wneu.2024.04.066_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary centralnervous system lymphoma: clinical features, outcome andprognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.04.066_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.wneu.2024.04.066_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2024.04.066_bib8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","article-title":"Ibrutinib brain distribution: a preclinical study","volume":"81","author":"Lauriane","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.wneu.2024.04.066_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2024.04.066_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.wneu.2024.04.066_bib11","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.21037\/tcr-21-50","article-title":"Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution","volume":"10","author":"Haifeng","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.wneu.2024.04.066_bib12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","article-title":"Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study","volume":"40","author":"Jing-Jing","year":"2022","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.wneu.2024.04.066_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.wneu.2024.04.066_bib14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.wneu.2024.04.066_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103010","article-title":"Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis","volume":"152","author":"Hou","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.wneu.2024.04.066_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2024.04.066_bib17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.wneu.2024.04.066_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2024.04.066_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Yoshitaka","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.04.066_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjh.16946","article-title":"Ibrutinib for central nervous system lymphoma: the Australasian lymphoma Alliance\/MD anderson cancer center experience","volume":"192","author":"Lewis","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.wneu.2024.04.066_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","article-title":"Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series","volume":"88","author":"Kamal","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2024.04.066_bib22","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.21873\/anticanres.15917","article-title":"Experience with tirabrutinib in the treatment of primary central nervous system lymphoma that is difficult to treat with standard treatment","volume":"42","author":"Hiromasa","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2024.04.066_bib23","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/bjh.16759","article-title":"Ibrutinib in patients with relapsed\/refractory central nervous system lymphoma: a retrospective single-centre analysis","volume":"190","author":"Lauer","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.wneu.2024.04.066_bib24","doi-asserted-by":"crossref","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series","volume":"12","author":"Yang","year":"2022","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.wneu.2024.04.066_bib25","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2019-125730","article-title":"Outcomes for patients with primary or secondary central system lymphoma treated with ibrutinib: a multicentre retrospective analysis","volume":"134","author":"Lewis","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2024.04.066_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2024.04.066_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.wneu.2024.04.066_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.04.066_bib29","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2024.04.066_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012-2017: a mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.wneu.2024.04.066_bib31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/CM9.0000000000000844","article-title":"Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin Med J"},{"key":"10.1016\/j.wneu.2024.04.066_bib32","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2024.04.066_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.wneu.2024.04.066_bib34","first-page":"483","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"P\u00a0T"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024006302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024006302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T06:22:36Z","timestamp":1727763756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875024006302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"alternative-id":["S1878875024006302"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2024.04.066","relation":{},"ISSN":["1878-8750"],"issn-type":[{"type":"print","value":"1878-8750"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2024.04.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 XI'an Gao Xin Hospital. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}